MALG
Phase 2Terminated 0 watching 0 views this week⚡ Active
52
Development Stage
✓
Pre-clinical✓
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Lice Infestations
Conditions
Lice Infestations
Trial Timeline
Feb 1, 2006 → Dec 1, 2006
NCT ID
NCT00291057About MALG
MALG is a phase 2 stage product being developed by Sun Pharmaceutical for Lice Infestations. The current trial status is terminated. This product is registered under clinical trial identifier NCT00291057. Target conditions include Lice Infestations.
Hype Score Breakdown
Clinical
17
Activity
12
Company
10
Novelty
5
Community
5
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT00291057 | Phase 2 | Terminated |
Competing Products
11 competing products in Lice Infestations
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| MALG + Ovide (malathion) lotion 0.05% + Permethrin 1% | Sun Pharmaceutical | Phase 3 | 77 |
| Ivermectin Lotion, 0.5% + SKLICE (ivermectin) Lotion, 0.5% + Vehicle of the Test product | Sun Pharmaceutical | Phase 1 | 33 |
| ivermectin + malathion | Johnson & Johnson | Phase 3 | 77 |
| Abametapir Lotion 0.74% w/w + Vehicle Lotion | Dr. Reddy's Laboratories | Phase 3 | 74 |
| Ha44 Gel 0.74% w/w | Dr. Reddy's Laboratories | Phase 2 | 49 |
| Abametapir Lotion 0.74% w/w + Vehicle Lotion | Dr. Reddy's Laboratories | Phase 3 | 74 |
| Abametapir Lotion 0.74% w/w | Dr. Reddy's Laboratories | Phase 1 | 30 |
| Abametapir Lotion 0.74% w/w + Sodium Lauryl Sulfate + Saline 0.9% + Placebo | Dr. Reddy's Laboratories | Phase 1 | 30 |
| Abametapir Lotion 0.74% w/w + Vehicle Lotion | Dr. Reddy's Laboratories | Phase 2 | 49 |
| Ha44 Gel | Dr. Reddy's Laboratories | Phase 2 | 49 |
| Ivermectin 0.5% Topical Application Lotion + Ivermectin 0.5% Topical Application Lotion [SKLICE] + Placebo 0% Lotion | Mayne Pharma Group | Phase 3 | 69 |
Other Products from Sun Pharmaceutical
Ilumya Injectable ProductApproved
85
CequaTM (Cyclosporine 0.09%) ophthalmic solutionApproved
85
Cyclosporine + Artificial tearApproved
85
AmifostineApproved
85
Ilaprazole antisecretory drug of each quadruple therapy the Ilaprazole -based quadruple therapy + Esoprazole antisecretory drug of each quadruple therapy Esoprazole-based quadruple therapyApproved
85